SCHEMBL4122528

SCHEMBL4122528

O=C(O)Cc1ccc(NC2=NC(=O)/C(=C\c3ccc(-c4ccc(O)cc4)cc3)S2)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 7/20 0.46
GRIN1 Q05586 2/20 0.41
GRIN2B Q13224 2/20 0.41
CA2 P00918 1/20 0.41
CAMK2A Q9UQM7 1/20 0.41
DCTPP1 Q9H773 1/20 0.40
AKR1B1 P15121 2/20 0.40
PTPN22 Q9Y2R2 1/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 1/20 0.38
FFAR1 O14842 1/20 0.38
PTPN1 P18031 1/20 0.38
ACP1 P24666 1/20 0.38
DUSP3 P51452 1/20 0.38
DUSP22 Q9NRW4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4122531 1.00 ALOX5 (0.46) ALOX5GRIN1GRIN2BCA2CAMK2A
SCHEMBL4132443 0.92 FFAR1 (0.47) ALOX5AKR1B1LMNAFFAR1DUSP3
SCHEMBL4132445 0.92 FFAR1 (0.47) ALOX5AKR1B1LMNAFFAR1DUSP3
SCHEMBL4634747 0.90 ALOX5 (0.52) ALOX5PTPN22MEN1KMT2APTPN1
SCHEMBL4634749 0.90 ALOX5 (0.52) ALOX5PTPN22MEN1KMT2APTPN1
SCHEMBL4635275 0.90 ALOX5 (0.42) ALOX5PTPN22KMT2AFFAR1DUSP3
SCHEMBL4127928 0.89 ALOX5 (0.53) ALOX5
SCHEMBL4127925 0.89 ALOX5 (0.53) ALOX5
SCHEMBL4133988 0.88 PDE4B (0.44) ALOX5PTPN22FFAR1PTPN1DUSP3
SCHEMBL4131357 0.88 ALOX5 (0.40) ALOX5AKR1B1PTPN22MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ ALOX5 3505/4885GRIN1 2032/4885GRIN2B 1658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.